Synthesis and discovery of N -carbonylpyrrolidine- or N -sulfonylpyrrolidine-containing uracil derivatives as potent human deoxyuridine triphosphatase inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 2960-2969

  Miyakoshi, Hitoshi ^a,c   Miyahara, Seiji ^a,b   Yokogawa, Tatsushi ^a   Chong, Khoon Tee ^a   Taguchi, Junko ^a   Endoh, Kanji ^a   Yano, Wakako ^a   Wakasa, Takeshi ^a   Ueno, Hiroyuki ^a   Takao, Yayoi ^a   Nomura, Makoto ^a   Shuto, Satoshi ^b   Nagasawa, Hideko ^c   Fukuoka, Masayoshi ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [2 (HYDROXYDIPHENYLMETHYL)PYRROLIDIN 1 YLSULFONYL]PROPYL]PYRIMIDIN 2, 4 (1H,3H)DIONE; 1 [4 [2 (HYDROXYDIPHENYLMETHYL)PYRROLIDIN 1 YL] 4 OXOBUTYL]PYRIMIDIN 2,4 (1H,3H)DIONE; ANTINEOPLASTIC AGENT; BIS(3 FLUOROPHENYL)(PYRROLIDIN 2 YL)METHANOL; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; ETHYL 2 [BIS(3 FLUOROPHENYL)(HYDROXY)METHYL]PYRROLIDIN 1 CARBOXYLIC ACID; FLOXURIDINE; N CARBONYLPYRROLIDINE; N SULFONYLPYRROLIDINE; PHENYL GROUP; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; FEMALE; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; RING OPENING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOXURIDINE; HELA CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYROPHOSPHATASES; PYRROLIDINES; SMALL MOLECULE LIBRARIES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDYLATE SYNTHASE; URACIL;

EID: 84859806910     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201627n     Document Type: Article

References (42)

1. Danneberg, P. B.; Montag, B. J.; Heidelberger, C. Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo Cancer Res. 1958, 18, 329-334
2. Harrap, K. R.; Jackman, A. L.; Newell, D. R.; Taylor, G. A.; Hughes, L. R.; Calvert, A. H. Thymidylate synthase: a target for anticancer drug design Adv. Enzyme Regul. 1989, 29, 161-179
3. Jackman, A. L.; Calvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs Ann. Oncol. 1995, 6, 871-881
4. Jackman, A. L.; Kelland, L. R.; Kimbell, R.; Brown, M.; Gibson, W.; Aherne, G. W.; Hardcastle, A.; Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines Br. J. Cancer 1995, 71, 914-924
5. Rhee, M. S.; Wang, Y.; Nair, M. G.; Galivan, J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity Cancer Res. 1993, 53, 2227-2230
6. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B.; Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin. Cancer Res. 2000, 6, 1322-1327
7. Popat, S.; Matakidou, A.; Houlston, R. S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis J. Clin. Oncol. 2004, 22, 529-536
8. Ladner, R. D.; Lynch, F. J.; Groshen, S.; Xiong, Y. P.; Sherrod, A.; Caradonna, S. J.; Stoehlmacher, J.; Lenz, H. J. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer Cancer Res. 2000, 60, 3493-3503
9. Galperin, M. Y.; Moroz, O. V.; Wilson, K. S.; Murzin, A. G. House cleaning, a part of good housekeeping Mol. Microbiol. 2006, 59, 5-19
10. Richardson, C. C.; Schildkraut, C. L.; Kornberg, A. Studies on the replication of DNA by DNA polymerases Cold Harbor Symp. Quantum Biol. 1963, 28, 9-19
11. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies Nature Rev. Cancer 2003, 3, 330-338
12. Curtin, N. J.; Harris, A. L.; Aherne, G. W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′- triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole Cancer Res. 1991, 51, 2346-2352
13. Webley, S. D.; Hardcastle, A.; Ladner, R. D.; Jackman, A. L.; Aherne, G. W. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331 Br. J. Cancer 2000, 83, 792-799
14. Mol, C. D.; Harris, J. M.; McIntosh, E. M.; Tainer, J. A. Human dUTP pyrophosphatase: uracil recognition by a beta hairpin and active sites formed by three separate subunits Structure 1996, 4, 1077-1092
15. Bertani, L. E.; Haeggmark, A.; Reichard, P. Enzymatic synthesis of deoxyribonucleotides. II. Formation and interconversion of deoxyuridine phosphates J. Biol. Chem. 1963, 238, 3407-3413
16. Grindey, G. R.; Nichol, C. A. Mammalian deoxyuridine 5′- triphosphate pyrophosphatase Biochim. Biophys. Acta 1971, 240, 180-183
17. McIntosh, E. M.; Haynes, R. H. dUTP pyrophosphatase as a potential target for chemotherapeutic drug development Acta Biochim. Pol. 1997, 44, 159-171
18. Caradonna, S. J.; Cheng, Y. C. The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells Mol. Pharmacol. 1980, 18, 513-520
19. An, Q.; Robins, P.; Lindahl, T.; Barnes, D. E. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity Cancer Res. 2007, 67, 940-945
20. Wilson, P. M.; Fazzone, W.; LaBonte, M. J.; Deng, J.; Neamati, N.; Ladner, R. D. Novel opportunities for thymidylate metabolism as a therapeutic target Mol. Cancer Ther. 2008, 7, 3029-3037
21. Ingraham, H. A.; Tseng, B. Y.; Goulian, M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine Mol. Pharmacol. 1982, 21, 211-216
22. Koehler, S. E.; Ladner, R. D. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition Mol. Pharmacol. 2004, 66, 620-626
23. Takatori, H.; Yamashita, T.; Honda, M.; Nishino, R.; Arai, K.; Takamura, H.; Ohta, T.; Zen, Y.; Kaneko, S. dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma Liver Int. 2010, 30, 438-446
24. Kawahara, A.; Akagi, Y.; Hattori, S.; Mizobe, T.; Shirouzu, K.; Ono, M.; Yanagawa, T.; Kuwano, M.; Kage, M. Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer J. Clin. Pathol. 2009, 62, 364-369
25. Zalud, P.; Wachs, W. O.; Nyman, P. O.; Zeppezauer, M. M. Inhibition of the proliferation of human cancer cells in vitro by substrate-analogous inhibitors of dUTPase Adv. Exp. Med. Biol. 1994, 370, 135-138
26. Persson, T.; Larsson, G.; Nyman, P. O. Synthesis of 2′-deoxyuridine 5′-(alpha,beta-imido) triphosphate: a substrate analogue and potent inhibitor of dUTPase Bioorg. Med. Chem. 1996, 4, 553-556
27. Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Perez, L. M.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target J. Med. Chem. 2005, 48, 5942-5954
28. Whittingham, J. L.; Leal, I.; Nguyen, C.; Kasinathan, G.; Bell, E.; Jones, A. F.; Berry, C.; Benito, A.; Turkenburg, J. P.; Dodson, E. J.; Ruiz Perez, L. M.; Wilkinson, A. J.; Johansson, N. G.; Brun, R.; Gilbert, I. H.; Gonzalez Pacanowska, D.; Wilson, K. S. dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors Structure 2005, 13, 329-338
29. Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Perez, L. M.; Sahlberg, B. L.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase J. Med. Chem. 2006, 49, 4183-4195
30. Jiang, Y. L.; Chung, S.; Krosky, D. J.; Stivers, J. T. Synthesis and high-throughput evaluation of triskelion uracil libraries for inhibition of human dUTPase and UNG2 Bioorg. Med. Chem. 2006, 14, 5666-5672
31. Mc Carthy, O. K.; Schipani, A.; Buendia, A. M.; Ruiz-Perez, L. M.; Kaiser, M.; Brun, R.; Pacanowska, D. G.; Gilbert, I. H. Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase Bioorg. Med. Chem. Lett. 2006, 16, 3809-3812
32. Beck, W. R.; Wright, G. E.; Nusbaum, N. J.; Chang, J. D.; Isselbacher, E. M. Enhancement of methotrexate cytotoxicity by uracil analogues that inhibit deoxyuridine triphosphate nucleotidohydrolase (dUTPase) activity Adv. Exp. Med. Biol. 1986, 195B, 97-104
33. Marriott, J. H.; Aherne, G. W.; Hardcastle, A.; Jarman, M. Synthesis of certain 2′-deoxyuridine derivatives containing substituted phenoxy groups attached to C-5′; evaluation as potential dUTP analogues Nucleosides, Nucleotides Nucleic Acids 2001, 20, 1691-1704
34. Hampton, S. E.; Baragana, B.; Schipani, A.; Bosch-Navarrete, C.; Musso-Buendia, J. A.; Recio, E.; Kaiser, M.; Whittingham, J. L.; Roberts, S. M.; Shevtsov, M.; Brannigan, J. A.; Kahnberg, P.; Brun, R.; Wilson, K. S.; Gonzalez-Pacanowska, D.; Johansson, N. G.; Gilbert, I. H. Design, synthesis, and evaluation of 5′-diphenyl nucleoside analogues as inhibitors of the Plasmodium falciparum dUTPase ChemMedChem 2011, 6, 1816-1831
35. Li, K.; Zhou, Z.; Wang, L.; Chen, Q.; Zhao, G.; Zhou, Q.; Tang, C. Asymmetric carbonyl reduction with borane catalized by chiral phosphinamides derived from l -amino acid Tetrahedron: Assymmetry 2003, 14, 95-100
36. Keuser, C.; Pindur, U. Oligopyrrole carboxamides linked with a nucleobase as potential DNA minor groove binding ligands: synthesis, DNA binding and biological evaluation Pharmazie 2006, 61, 261-268
37. Ahn, H.; Choi, T. H.; De Castro, K.; Lee, K. C.; Kim, B.; Moon, B. S.; Hong, S. H.; Lee, J. C.; Chun, K. S.; Cheon, G. J.; Lim, S. M.; An, G. I.; Rhee, H. Synthesis and evaluation of cis -1-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-5- [(124)I]iodouracil: a new potential PET imaging agent for HSV1-tk expression J. Med. Chem. 2007, 50, 6032-6038
38. Lipinsky, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting Adv. Drug Delivery Rev. 1997, 23, 3-25
39. Varga, B.; Barabas, O.; Kovari, J.; Toth, J.; Hunyadi-Gulyas, E.; Klement, E.; Medzihradszky, K. F.; Tolgyesi, F.; Fidy, J.; Vertessy, B. G. Active site closure facilitates juxtaposition of reactant atoms for initiation of catalysis by human dUTPase FEBS Lett. 2007, 581, 4783-4788
40. Fernandez, A.; Scott, R. Dehydron: a structurally encoded signal for protein interaction Biophys. J. 2003, 85, 1914-1928
41. Fernandez, A.; Maddipati, S. A priori inference of cross reactivity for drug-targeted kinases J. Med. Chem. 2006, 49, 3092-3100
42. Fernandez, A.; Sanguino, A.; Peng, Z.; Ozturk, E.; Chen, J.; Crespo, A.; Wulf, S.; Shavrin, A.; Qin, C.; Ma, J.; Trent, J.; Lin, Y.; Han, H. D.; Mangala, L. S.; Bankson, J. A.; Gelovani, J.; Samarel, A.; Bornmann, W.; Sood, A. K.; Lopez-Berestein, G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic J. Clin. Invest. 2007, 117, 4044-4054